Inclusion Criteria:

• CKD stage 3 (eGFR 30-59 ml/min/1.73m² [according to the currently used estimation formulas: MDRD, CKD-EPI]) with diabetic or non-diabetic nephropathy
• Uncontrolled hypertension with 1-5 drug classes (renin angiotensin system [RAS] blockade is mandatory, unless intolerance to RAS blockers has been documented) and systolic office (attended) BP ≥140 mmHg confirmed by 24-h ambulatory BP systolic ≥130 mmHg
• Patient is adhering to a stable drug regimen including RAS blockade without changes for a minimum of 4 weeks.
• Individual is ≥ 18 years of age, both genders are included

Exclusion Criteria:

• Anatomically significant renal artery abnormality in either renal artery which in the eyes of the interventionalist would interfere with safe catheter Placement
• Other cause of Hypertension that can be treated by Intervention/surgery (e.g. hemodynamically relevant renal artery stenosis, functional adrenal adenoma)
• Prior renal denervation procedure
• Office (attended) BP ≥ 180 mmHg systolic and/or ≥ 110 mmHg diastolic
• 24-h ambulatory BP ≥ 160 mmHg systolic
• Anatomic or functional solitary kidney, kidney transplantation
• Lack of capturing serum creatinine levels in the past
• Secondary hypertension other than obstructive sleep apnea
• Type 1 diabetes mellitus
• Nephrotic syndrome
• Contraindication to magnetic resonance imaging (MRI)
• Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit
• Acute episode of renal disease requiring uptitration of any immunosuppressive drug regimen within the last 3 months
• Subject is pregnant, nursing, or intends to become pregnant
• Enrollment in another interventional research protocol.
• Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence)